- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 605-94-7] Coenzyme Q0
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-W016412 |
| Brand: | MCE |
| CAS: | 605-94-7 |
Overview
| MDL | MFCD00001595 |
|---|---|
| Molecular Weight | 182.18 |
| Molecular Formula | C9H10O4 |
| SMILES | O=C1C(OC)=C(OC)C(C(C)=C1)=O |
Summary
Coenzyme Q0 (CoQ0) is a potent, oral active ubiquinone compound can be derived from Antrodia cinnamomea . Coenzyme Q0 induces apoptosis and autophagy , suppresses of HER-2/AKT/mTOR signaling to potentiate the apoptosis and autophagy mechanisms. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of inflammation and redox imbalance. Coenzyme Q0 has anti-angiogenic activity through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling [1] [2] [3] .
In Vitro
Coenzyme Q0 (0-40 µM; 24 h) and inhibits viability and growth of human ovarian carcinoma cells
[1]
.
Coenzyme Q0 (CoQ0) (0-30 µM; 24 h; SKOV-3 cells) has anti-proliferative activity through induction of G2/M cell-cycle arrest and reduction of cell-cycle regulatory proteins
[1]
.
Coenzyme Q0 (CoQ0) (0-30 µM; 0-30 min; SKOV-3 cells) increases intracellular ROS levels to promote SKOV-3 cell death
[1]
.
Coenzyme Q0 (CoQ0) (0-30 µM; 24 h; SKOV-3 cells) induces autophagy by increase accumulation of LC3-II, GFP-LC3 puncta, AVOs formation and Beclin-1/Bcl-2 dysregulation
[1]
.
Coenzyme Q0 (CoQ0) (0-30 µM; 24 h; SKOV-3 cells) induces apoptosis by mitochondrial (caspase-3, PARP and Bax/Bcl-2 dysregulation) and ER stress (caspase-12 and Hsp70) signals
[1]
.
Coenzyme Q0 (CoQ0) (30 µM; 24 h; SKOV-3 cells) suppresses of HER-2/AKT/mTOR signaling to potentiate the apoptosis and autophagy mechanisms
[1]
.
Coenzyme Q0 (CoQ0) (0-10 µM; 0.5-18 h; RAW264.7 cells) regulates NFκB/AP-1 activation and enhances Nrf2 stabilization
[2]
.
Coenzyme Q0 (CoQ0) (5 µM; 0-12 h; EA.hy 926 cells) has anti-angiogenic activity in EA.hy 926 cells
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | SKOV-3, A2780 and A2870/CP70 cells |
| Concentration: | 0, 10, 20, 30 and 40 µM |
| Incubation Time: | 24 hours |
| Result: | Decreased viability with the IC 50 values of 26.6 µM, 27.3 µM and 28.4 µM for SKOV-3, A2780 and A2870/CP70 cells, respectively. |
Cell Cycle Analysis [1]
| Cell Line: | SKOV-3, A2780 and A2870/CP70 cells |
| Concentration: | 0, 10, 20 and 30 µM |
| Incubation Time: | 24 hours |
| Result: | Arrested cell cycle at G2/M phase and reduced cell-cycle proteins in SKOV-3 cells. |
Apoptosis Analysis [1]
| Cell Line: | SKOV-3, A2780 and A2870/CP70 cells |
| Concentration: | 0, 5, 15 and 30 µM |
| Incubation Time: | 24 hours |
| Result: | Promoted the conversion of LC3–1 to LC3-II and increased the LC3-II accumulation. Increased Bax/Bcl-2 ratio in a dose-dependent manner. |
Apoptosis Analysis [1]
| Cell Line: | SKOV-3 cells |
| Concentration: | 0, 10, 20 and 30 µM |
| Incubation Time: | 24 hours |
| Result: | Had the percentage of early apoptotic cells are 25.1%, 34% and 36% for 10, 20 and 30 µM, respectively. |
Western Blot Analysis [1]
| Cell Line: | SKOV-3 cells |
| Concentration: | 0, 5, 15 and 30 µM |
| Incubation Time: | 24 hours |
| Result: | Activated of caspase-3 and cleavaged of PARP. Increased the expressions of caspase-12, HSP-70 and Bax in a dose-dependent manner, decreased the expressions of Bcl-2. |
Western Blot Analysis [1]
| Cell Line: | SKOV-3 cells |
| Concentration: | 30 µM |
| Incubation Time: | 24 hours |
| Result: | Decreased the phosphorylated HER-2 (Y1221) levels, p-AKT (Ser473) and p-mTOR (S2448) levels. |
Western Blot Analysis [2]
| Cell Line: | RAW264.7 cells |
| Concentration: | 0, 2.5, 5 and 10 µM |
| Incubation Time: | 0.5-18 hours |
| Result: | Inhibited iNOS/COX-2 protein expressions with reductions of NO, PGE2, TNF-α and IL-1β secretions. |
Western Blot Analysis [3]
| Cell Line: | EA.hy 926 cells |
| Concentration: | 5 µM |
| Incubation Time: | 0, 1, 3, 6 and 12 hours |
| Result: | Increased expressions of heme oxygenase-1 (HO-1) and γ-glutamylcysteine synthetase (γ-GCLC), inhibits protein expressions of matrix metalloproteinase-9 (MMP-9), reduces TNF-α-induced nuclear translocation and transcriptional activation of nuclear factor-κB (NF-κB). |
In Vivo
Coenzyme Q0 (CoQ0) (1.5 and 2.5 mg/kg; i.p.; once every four days, for 52 d) suppresses tumor growth in SKOV-3 xenografted nude mice
[1]
.
Coenzyme Q0(CoQ0) (5 mg/kg; p.o.; for 4 h) has anti-inflammatory activities through Nrf2 activation and NFκB inhibition in liver and spleen of LPS-treated mice
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | SKOV-3 xenografted nude mice [1] |
| Dosage: | 1.5 and 2.5 mg/kg |
| Administration: | Intraperitoneal injection; Once every four days, for 52 days |
| Result: | Inhibited the tumor growth at 1.5 and 2.5 mg/kg. |
| Animal Model: | LPS-treated female FVB mice [2] |
| Dosage: | 5 mg/kg |
| Administration: | Oral administration; for 4 hours |
| Result: | Down-regulates inflammatory genes in liver and spleen tissues of LPS injected mice. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 274.45 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 5.4891 mL | 27.4454 mL | 54.8908 mL |
| 5 mM | 1.0978 mL | 5.4891 mL | 10.9782 mL |
| 10 mM | 0.5489 mL | 2.7445 mL | 5.4891 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1.67 mg/mL (9.17 mM); Clear solution
References
- [1] Yang HL, et, al. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of LPS-induced inflammation and redox imbalance: Evidence from in vitro and in vivo studies. Biochim Biophys Acta. 2016 Feb;1859(2):246-61.
- [2] Yang HL, et, al. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of LPS-induced inflammation and redox imbalance: Evidence from in vitro and in vivo studies. Biochim Biophys Acta. 2016 Feb;1859(2):246-61.
- [3] Yang HL, et, al. Anti-angiogenic properties of coenzyme Q0 through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling in TNF-α-activated human endothelial cells. Biochem Pharmacol. 2015 Nov 1;98(1):144-56.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.